A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

2024/09/24 by Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri +28 · 3 citations
Medicine · #Acute Myeloid Leukemia Research #Cancer Treatment and Pharmacology #Multiple Myeloma Research and Treatments

paper · pdf · doi:10.1182/blood.2024025834

Abstract

ABSTRACT: A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for patients with acute myeloid leukemia and a TP53-mutation was 16.1 and 11.3 months, respectively. This trial was registered at www.clinicaltrials.gov as #NCT05184842.

Cited by

• Molecular and Clinical Insights into TP53 -Mutated MDS and AML. [europepmc]
• Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia. [europepmc]
• The Spectrum of Venetoclax-Based Treatments in Acute Myeloid Leukemia. [europepmc]

Related

• Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
• Decitabine improves patient outcomes in myelodysplastic syndromes
• Abstract 939: The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells
• Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
• Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)